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Sir, The optimum therapy of patients with severe infections caused by high-level gentamicin-resistant (HLGR) enterococci has not yet been determined. In a previous study, the combination of ampicillin and ciprofloxacin was found to be bactericidal against such strains in vitro. 1 However, the same combination failed to sterilize valvular vegetations in an experimental endocarditis model. 2 In an attempt to explain this discrepancy, we evaluated the effects of different media, varying the Ca 2+ and Mg 2+ concentrations of the medium and the presence or absence of human serum in the medium on the activities of the ampicillinciprofloxacin combination against five HLGR, ampicillinand ciprofloxacin-resistant clinical isolates of Enterococcus faecium.
The MICs of ampicillin and ciprofloxacin (both obtained from Sigma Chemical Co., St Louis, MO, USA) were determined by a microbroth dilution method. 1 The media used in the study were as follows: Mueller-Hinton broth (MHB; Difco, Detroit, MI, USA), cation-adjusted Mueller-Hinton II broth (MHB II; BBL Becton Dickinson, Cockeysville, MD, USA), Brain Heart Infusion broth (BHI; Difco), MHB supplemented with 50% pooled human serum (HS-MHB) and MHB supplemented with Ca 2+ and Mg 2+ to give final concentrations of 50 mg/L and 25 mg/L respectively (Ca 2+ /Mg 2+ -MHB). Time-kill studies were performed with ampicillin alone, ciprofloxacin alone, both ampicillin and ciprofloxacin or no antibiotic (control) according to a method described previously; 1 the concentrations of ampicillin and ciprofloxacin were 20 mg/L and 2 mg/L respectively. An overnight culture of each strain was diluted in each of the five media to give suspensions that initially contained 10 9 cfu/L. Bactericidal activity was defined as a reduction in the initial suspension of 3 log 10 cfu/L after incubation at 37ºC for 24 h. All of the experiments were performed at least twice and the results expressed as the means.
The MICs of ampicillin and ciprofloxacin for the five enterococcal strains in MHB, MHB II, BHI and Ca 2+ /Mg 2+ -MHB were 32-64 mg/L and 2-4 mg/L respectively. The MICs of ampicillin in HS-MHB were markedly higher, i.e. 128-256 mg/L, while those of ciprofloxacin in this medium were only slightly higher, i.e. 4-8 mg/L. The results of the time-kill studies are shown in the Table. Ampicillin consistently failed to exhibit more than marginal inhibitory activity against any of the strains. Ciprofloxacin, on the other hand, exhibited bacteriostatic activity against all strains in MHB, MHB II and BHI, although its inhibitory activities in HS-MHB and Ca 2+ /Mg 2+ -MHB were minimal. In attempting to correlate bacterial survival in the presence of ciprofloxacin with the cation content of the medium (Table) , we demonstrated a significant inverse relationship between ciprofloxacin inhibitory activity and Mg 2+ concentration with all strains (r 0.84-0.94; P 0.05) and Ca 2+ concentration with four of the five strains (r 0.86-0.94; P 0.05). These data confirm the earlier observation that divalent cations antagonize the in-vitro activities of quinolone antibiotics. 3 The combination of ampicillin and ciprofloxacin was bactericidal against all strains in MHB and against one of the five strains in MHB II, although, for the remaining four strains, the effect was just below the criterion that defined bactericidal activity, i.e. 2.56-2.99 log 10 cfu/L; synergy between the two agents was observed with all strains in both media. In contrast, the combination exhibited only bacteriostatic activity against all strains in BHI and HS-MHB. Finally, in Ca 2+ /Mg 2+ -MHB, it was bactericidal against two strains and exhibited activity that was just below the threshold that defined bactericidal activity (2.37-2.84 log 10 cfu/L) for the remaining three strains; synergy was observed with all five isolates. The bactericidal activity of the combination in this medium was therefore similar to that in MHB, even though the activity of ciprofloxacin in the former was markedly lower than that in the latter.
The failure of the antibiotic combination to exhibit bactericidal activity in enriched media (BHI and HS-Correspondence © 1998 The British Society for Antimicrobial Chemotherapy JAC Correspondence MHB) might be accounted for by one or more of the following factors: the expression of high-level resistance to ampicillin in HS-MHB; the reduced activity of ciprofloxacin in the presence of a high cation concentration; and a possible inoculum effect in enriched media, such as BHI and HS-MHB, in which bacterial growth proceeds at a faster rate, thereby reaching the stationary phase of growth earlier, with a consequent reduction in the oxygen tension of the medium (anaerobic conditions having been shown previously to reduce the bactericidal activity of ciprofloxacin 4 ). Thus, when none of these factors were present, i.e. low-level resistance to ampicillin, a low cation content and no inoculum effect, as in MHB, the activity of the combination was greatest. Conversely, when all three were present, as in HS-MHB, the activity was lowest. When one or two factors were present (MHB II and Ca 2+ /Mg 2+ -MHB), the activity of the combination fell between the two extremes.
The results of this study demonstrate that the in-vitro bactericidal activity of the ampicillin-ciprofloxacin combination varies according to the composition of the medium in which the activity is being determined. We have also shown that the activity of the combination in BHI is similar to that in HS-MHB. Therefore, BHI appears to be a more suitable medium, at least for enterococci, when evaluating the in-vitro activities of antibiotic combinations, the results of which may have implications for therapy.
We conclude that the combination of ampicillin and ciprofloxacin may have a role in the treatment of patients with severe infections caused by HLGR enterococci, provided that the aetiological agent does not exhibit highlevel resistance to either antibiotic and the combination has been shown to be bactericidal in BHI. Sir, Monitoring vancomycin serum concentrations has traditionally relied on determining both troughs and peaks. However, it has been proposed 1 that all of the information necessary to ensure that non-toxic, therapeutic concentrations are achieved can be obtained by measuring trough concentrations only, because (i) the post-dose increase is sufficiently predictable with standard dosing regimens and (ii) excessively high peaks do not occur in the absence of accumulation and corresponding elevated trough concentrations. Studies in adults have supported this proposal 2 and a retrospective analysis suggested that the practice could also be applied to preterm infants. 3 We describe a prospective study in neonates in which both trough and peak concentrations were measured in order to determine whether or not troughonly monitoring can be extended to this pharmacokinetically distinctive population.
Trough-only monitoring of serum vancomycin concentrations in neonates
All patients on the neonatal unit of the John Radcliffe Hospital who received vancomycin between August 1995 and July 1996 were eligible for inclusion in the study. The dosing schedule was that recommended by Koren & James;
4 patients were given a standard initial dosage of 25 mg/kg/dose and the interval between doses was based on body weight, i.e. every 36 h if the patient weighed 800 g, every 24 h if the weight was between 800 and 1200 g and every 12 h if the weight was 1200 g. The recommended ranges for pre-dose (trough) concentrations and for 1 h post-infusion (peak) concentrations were 5-10 mg/L and 30-40 mg/L respectively. Serum concentrations were measured by a fluorescence polarization immunoassay (Biostat Diagnostics Ltd, Stockport, UK).
Sixty-four paired trough and peak samples were obtained from 26 patients; one pair was excluded from analysis because of a probable sampling or drug administration error that yielded a post-dose increase of 10 mg/L, a result that was also inconsistent with those previously determined for the same patient. The Figure  shows the dose-associated increases in the serum drug concentrations. The mean increase was 28.7 5.9 mg/L. Peak concentrations exceeded 40 mg/L on 17 (27%) occasions. Of these 17 pairs of samples, pre-dose concentrations were 12 mg/L (range 12.1-24.1 mg/L) in eight, 10-12 mg/L (the corresponding peaks did not exceed 45 mg/L) in three and 10 mg/L in six. These last six pairs of results related to two premature infants with complex neonatal problems who were already severely ill when antibiotic treatment was commenced and who already had raised serum creatinine concentrations; one infant was hypotensive during one of the courses of treatment. These patients are similar to the two with high peak concentrations, but without elevated pre-dose concentrations, described by de Hoog et al. in a retrospective study. 3 The use of a dosing regimen based on body weight in this patient population resulted in consistent incremental increases in vancomycin serum concentrations. The mean post-dose increase was markedly greater than that observed previously in adults 1 (28.7 mg/L vs 16.6 mg/L), although the variabilities were similar (standard deviations 5.9 mg/L vs 6.1 mg/L). The discrepancy in the post-dose increase can be accounted for by the administration of higher dosages (in relation to body weight) to neonates than are normally given to adults, i.e. a 1 g dose given to a 70 kg adult is equivalent to 14.3 mg/kg, compared with the neonates enrolled in this study who received dosages of 25 mg/kg. None the less, post-dose concentrations could be predicted on the basis of predose concentrations as reliably as in adults. The peak concentrations were higher in neonates, thereby reflecting the higher dosage administered. Indeed, the actual increase in serum concentration (mg/L) in relation to the body weight-based dosage (mg/kg) was remarkably similar in adults 1 and neonates (1.15 and 1.16 kg/L, respectively).
This study, in common with a previous study in adults, 1 has made no attempt to relate the clinical efficacy of vancomycin to the concentrations measured. However, both studies were performed in the context of the recent reassessment of vancomycin monitoring. 5, 6 Two important points should be borne in mind. Firstly, the maintenance of adequate trough concentrations is the principal determinant of bactericidal activity and, secondly, whilst elevated trough concentrations are predictive of accumulation and subsequent deterioration in renal function, post-dose concentrations have not been proven to be predictive of either outcome or toxicity. 6 In this context, the higher post-dose concentrations observed in the present study, when compared with the corresponding values in adults, are unlikely to be associated with increased toxicity in the absence of accumulation, as demonstrated by the failure to detect elevated pre-dose concentrations. Of greater concern, however, is the proportion of pre-dose concentrations that were 5 mg/L, i.e. 27 of 63 (43%). The dosing regimen employed was based on one designed to ensure peaks of 40 mg/L without reference to a lower limit. 4 The use of higher body weightbased dosages (assuming no associated toxicity) has the advantage of allowing the dosing interval to be increased, a facility that is important in neonatal practice. The low trough concentrations recorded in this study (irrespective of the dosing interval, although the lowest concentrations were observed in patients receiving doses every 24 or 36 h) suggest that dosing may need to be adjusted, perhaps by reducing the dosing interval, in order to optimize the efficacy of therapy. 1 reported on the pharmacokinetics of amikacin, 35 mg/kg body weight, given as a single daily dose to 18 paediatric patients with cystic fibrosis; serum concentrations were determined by fluorescence polarization (TDx, Abbott Laboratories, Chicago, IL, USA). The results of their analysis, based on a two-compartment model, are summarized in the Table. While the total body clearance (Cl) is comparable to those determined by previous investigators, 2,3 the volume of distribution (V d ) and half-life (T1 / 2 ) are much higher.
Pharmacokinetics of once-daily amikacin dosing in patients with cystic fibrosis
Vogelstein et al. 2 studied the pharmacokinetics of amikacin in 20 children and adolescents who were given four doses of 420 mg/m 2 at 8 h intervals; an enzymatic assay was used to measure serum concentrations. Pharmacokinetic analysis with non-compartmental methods demonstrated a markedly smaller V d and a shorter elimination T1 / 2 in patients with cystic fibrosis (n = 11) compared with the values of these parameters reported by Canis et al. 1 (Table) . In a third study, Autret et al. 3 performed 36 pharmacokinetic evaluations involving nine patients with cystic fibrosis (mean age 7.6 years). The patients received amikacin in dosages of 5-12.5 mg/kg body weight every 6-12 h; serum concentrations were determined by fluorescence polarization (TDx, Abbott Laboratories). The results, based on a one-compartment open model, were very similar to those reported by Vogelstein et al. (Table) .
The three studies are comparable in terms of the patients' ages, weights, etc. The only major difference between the study of Canis et al. 1 and those of Vogelstein et al. 2 and Autret et al. 3 is in the dosing regimen: Canis et al. 1 administered the drug as a once-daily infusion, while the other investigators gave it in multiple daily doses. However, a recent pharmacokinetic study, 4 in which onceand multiple-daily dosing were compared, did not reveal any dose-dependent changes in the V d that could account for the differences described above. In addition, although slight differences might be expected, owing to varying pharmacokinetic methods (i.e. the use of non-compartmental, one-compartment or two-compartment models), these would not explain the five-fold increase in V d (or the greater than two-fold increase in the elimination half-life (T1 / 2 ) reported by Canis et al. 1 In an attempt to identify factors that would account for the discrepant values, we performed a curve-fitting analysis of their mean serum concentration-time data with MW/PHARM (MediWare, Groningen, The Netherlands); the analysis included assessment of various weighting schemes. Analysis with a two-compartment model and weighting the data by a constant (5%) coefficient of variation (CV) yielded values that were similar to those of Canis et al. 1 (Table) . However, when the same data were fitted with weighting by the reciprocal of the concentration (1/C), as is often done, markedly different results, but similar to those reported by both Vogelstein et al. 2 and Autret et al.
3
, were obtained (Table) .
A probable explanation for the discrepancy in the data generated by the different weighting schemes concerns the assumed assay precision. Most assays exhibit error patterns, the standard deviations (S.D.) of which vary, often in a non-linear manner, throughout the overall range of the assay. 5 For the optimal fitting method, the assay error pattern should be experimentally determined at all relevant concentrations in order that the S.D. of each measured serum concentration can be known. Incorporation of the appropriate error pattern for each assay used for population pharmacokinetic analysis gives maximum reliability to serum concentration data that have been weighted by 1/S.D. 2 and has been demonstrated to be superior to other methods. 6 While insufficient information is available to determine explicitly the error pattern of the assay of Canis et al. Angeles, CA, USA) of the mean serum concentration data generated by Canis et al. 1 with weighting by the reciprocal of the error variance (1/S.D. 2 , Table) . The results are consistent with those reported by previous investigators and comparable to those found with weighting by the reciprocal of the concentration (1/C, Table) , but different from those reported by Canis et al. 1 Our analysis suggests that the discrepancy between the pharmacokinetic parameters determined by Canis et al. 1 and those of other investigators can be explained by the former's method of weighting the serum concentration data. Weighting by the reciprocal of S.D. 2 and using the explicitly determined assay error pattern is the preferred method. The use of a polynomial equation which describes the error pattern for the assay of amikacin by the Abbott TDx and which was derived from data from the CAP surveys 5 resulted in values for the pharmacokinetic parameters that are more consistent with those determined in previous studies. These findings underscore the importance of assigning the true weight to serum concentration data and the need, when reporting such findings, to specify the method by which the pharmacokinetic analysis was performed, including the weighting method utilized. Too often, assay precision is evaluated merely for the purpose of ascertaining whether or not it is acceptable and is then ignored in the actual fitting process. It is well known that different weighting schemes result in values for pharmacokinetic parameters that are markedly different. In what, then, should we place our trust? We believe that only the experimentally determined explicit error pattern of the assay should be used, whenever possible.
